$11.8MSeries A, 25 February 2026
Series A to accelerate CoagCare development for bleeding and transfusion decisions.
- Amount
- $11.8M
- Stage
- Series A
- Announced
- 25 February 2026
- Lead
- Octapharma
- Use of funds
- Series A to accelerate CoagCare development for bleeding and transfusion decisions.
- Checked
- Announced by the company
- Sources
- Abram Scientific secures $11.75M Series A led by Octapharma biospace.com
Abram Scientific secures $11.75M Series A led by Octapharma prnewswire.com